Aesica Pharmaceuticals is doubling development capacity at its Queenborough facility, and will now be able to develop and manufacture multiple products from early formulation development through Phase III clinical manufacture and into commercialization.

The company’s high potent and controlled drugs service offering has been significantly expanded. The site handles high potent drugs for any active up to SafeBridge Category 3, together with controlled drugs, with licenses for both Schedules 2 to 4.

Ian Muir, managing director of Aesica Pharmaceuticals said, “In response to growing customer demand, and as part of our on-going strategy to meet the needs of the market to simplify the supply chain with reliable, highly efficient, single source solutions, we have taken the strategic initiative to ensure that our high capacity Queenborough Development Centre, which doubles our development capacity, combined with our commercial manufacturing capabilities at the facility, provides a complete service offering for formulation, development and product manufacturing for multiple customers.”

He added, “High potency is a key contract services market, with strong growth potential, requiring a mix of highly specialized and advanced technological skills and capabilities. We have set these resources in place and have now taken the strategic initiative to combine them with full clinical and commercial scale manufacturing capacity in this highly complex field from a single site location – further enhancing our offering to customers.”